|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/18 DelMar Pharmaceuticals, Inc. 10-Q 9/30/18 53:3.3M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 267K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
12: R1 Document and Entity Information HTML 42K
13: R2 Consolidated Condensed Interim Balance Sheets HTML 80K
(Unaudited)
14: R3 Consolidated Condensed Interim Balance Sheets HTML 36K
(Parenthetical) (Unaudited)
15: R4 Consolidated Condensed Interim Statements of Loss HTML 56K
and Comprehensive Loss (Unaudited)
16: R5 Consolidated Condensed Interim Statements of Cash HTML 68K
Flows (Unaudited)
17: R6 Going Concern, Nature of Operations, and Corporate HTML 36K
History
18: R7 Significant Accounting Policies HTML 51K
19: R8 Valent Technologies, LLC HTML 21K
20: R9 Derivative Liability HTML 34K
21: R10 Stockholders' Equity HTML 152K
22: R11 Financial Instruments HTML 41K
23: R12 Supplementary Statement of Cash Flows Information HTML 23K
24: R13 Subsequent Events HTML 21K
25: R14 Significant Accounting Policies (Policies) HTML 58K
26: R15 Derivative Liability (Tables) HTML 36K
27: R16 Stockholders' Equity (Tables) HTML 127K
28: R17 Financial Instruments (Tables) HTML 24K
29: R18 Supplementary Statement of Cash Flows Information HTML 21K
(Tables)
30: R19 Going Concern, Nature of Operations, and Corporate HTML 32K
History (Details)
31: R20 Significant Accounting Policies (Details) HTML 27K
32: R21 Valent Technologies, LLC (Details) HTML 37K
33: R22 Derivative Liability (Details) HTML 28K
34: R23 Derivative Liability (Details 1) HTML 29K
35: R24 Stockholders' Equity (Details) HTML 61K
36: R25 Stockholders' Equity (Details 1) HTML 32K
37: R26 Stockholders' Equity (Details 2) HTML 24K
38: R27 Stockholders' Equity (Details 3) HTML 91K
39: R28 Stockholders' Equity (Details 4) HTML 32K
40: R29 Stockholders' Equity (Details 5) HTML 24K
41: R30 Stockholders' Equity (Details 6) HTML 33K
42: R31 Stockholders' Equity (Details 7) HTML 25K
43: R32 Stockholders' Equity (Details 8) HTML 65K
44: R33 Stockholders' Equity (Details Textual) HTML 69K
45: R34 Stockholders' Equity (Details Textual 1) HTML 35K
46: R35 Stockholders' Equity (Details Textual 2) HTML 38K
47: R36 Stockholders' Equity (Details Textual 3) HTML 39K
48: R37 Financial Instruments (Details) HTML 24K
49: R38 Supplementary Statement of Cash Flows Information HTML 24K
(Details)
50: R39 Subsequent Events (Details) HTML 35K
52: XML IDEA XML File -- Filing Summary XML 90K
51: EXCEL IDEA Workbook of Financial Reports XLSX 49K
6: EX-101.INS XBRL Instance -- dmpi-20180930 XML 937K
8: EX-101.CAL XBRL Calculations -- dmpi-20180930_cal XML 72K
9: EX-101.DEF XBRL Definitions -- dmpi-20180930_def XML 435K
10: EX-101.LAB XBRL Labels -- dmpi-20180930_lab XML 845K
11: EX-101.PRE XBRL Presentations -- dmpi-20180930_pre XML 595K
7: EX-101.SCH XBRL Schema -- dmpi-20180930 XSD 140K
53: ZIP XBRL Zipped Folder -- 0001213900-18-015493-xbrl Zip 90K
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of DelMar Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Praill, Chief Financial Officer of the Company, certify to my knowledge and in my capacity, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 13, 2018
|
/s/ Scott Praill |
|
| Scott Praill | |
| Chief Financial Officer (Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/13/18 | 4 | ||
| For Period end: | 9/30/18 | |||
| List all Filings | ||||